CRSP - CRISPR Therapeutics AG
60
1.940 3.233%
Share volume: 1,170,589
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$58.06
1.94
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-08-2024 | 08-05-2024 | 11-05-2024 | 02-11-2025 | 05-06-2025 | 08-04-2025 | 11-10-2025 | 02-12-2026 | |
| Assets | |||||||||
| Total Assets | 2.439 B | 2.340 B | 2.256 B | 2.242 B | 2.166 B | 2.030 B | 2.245 B | 2.265 B | |
| Current Assets | 2.120 B | 2.010 B | 1.944 B | 1.937 B | 1.868 B | 1.734 B | 1.929 B | 1.986 B | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 1.401 B | 1.517 B | 1.710 B | 1.606 B | 1.620 B | 1.528 B | 1.629 B | 1.628 B | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 707.427 M | 484.472 M | 225.670 M | 298.257 M | 235.184 M | 193.618 M | 286.497 M | 347.559 M | |
| Total Non-current Assets | 0.000 | 11.216 M | 0.000 | 0.000 | 0.000 | 0.000 | 28.412 M | 0.000 | |
| Property Plant Equipment | 147.253 M | 143.031 M | 138.542 M | 134.093 M | 129.426 M | 124.926 M | 120.831 M | 115.851 M | |
| Other Assets | 172.140 M | 186.415 M | 173.697 M | 170.809 M | 169.065 M | 171.119 M | 195.385 M | 163.721 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.439 B | 2.340 B | 2.256 B | 2.242 B | 2.166 B | 2.030 B | 2.245 B | 2.265 B | |
| Total liabilities | 355.081 M | 358.904 M | 316.472 M | 309.954 M | 336.942 M | 318.586 M | 329.326 M | 343.430 M | |
| Total current liabilities | 118.990 M | 127.823 M | 89.810 M | 87.782 M | 119.447 M | 104.362 M | 118.957 M | 149.120 M | |
| Accounts Payable | 16.463 M | 9.452 M | 15.578 M | 14.709 M | 13.064 M | 9.753 M | 11.798 M | 11.138 M | |
| Other liabilities | 222.550 M | 218.498 M | 214.339 M | 209.849 M | 205.172 M | 201.901 M | 198.046 M | 194.310 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 222.550 M | 218.498 M | 214.339 M | 209.849 M | 205.172 M | 201.901 M | 198.046 M | 194.310 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 2.084 B | 1.981 B | 1.940 B | 1.932 B | 1.829 B | 1.711 B | 1.916 B | 1.922 B | |
| Common stock | 3.202 B | 3.227 B | 3.258 B | 3.296 B | 3.327 B | 3.418 B | 3.728 B | 3.865 B | |
| Retained earnings | -1.116 B | -1.243 B | -1.329 B | -1.366 B | -1.502 B | -1.710 B | -1.817 B | -1.948 B |